China’s new insurance administration is looking to create bigger discounts on cancer treatments on its National Reimbursement Drug List (NRDL), according to a Fierce Pharma report.
The agency would involve a public bidding and procurement process aimed solely at cancer treatments. Chinese officials reportedly will commence enlistment talks for drugs yet to be added to the NRDL.
According to Fierce Pharma, China’s renewed focus on cancer treatment costs was announced during a conference in April prior to lifting import tariffs and pulling back the import value-added tax to three percent on all cancer drugs.
As a result of the insurance administration’s new drug review process, innovative treatments such as AstraZeneca’s Tagrisso and Bristol-Myers Squibb’s Opdivo are making swift entries into the marketplace.